Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1985-11-8
|
| pubmed:abstractText |
Compound LY171883 caused dose-related and reversible hepatomegaly in male Fischer 344 rats. Histological examination revealed hepatocellular hypertrophy with no other evidence of liver disease. There were only minor changes in serum glucose, total bilirubin, alkaline phosphatase, and alanine transaminase which were generally unrelated to dose and dissociable from the hepatomegaly. Total liver DNA increased but the DNA concentration decreased, indicating that liver growth involved a combination of hypertrophy and hyperplasia. Total liver protein and RNA increased. Hepatic mitochondrial protein content increased but cytochrome oxidase activity was not changed. There were minor changes in mitochondrial respiratory parameters; however, all the values were in the normal range and there was no indication of mitochondrial toxicity. Microsomal protein, drug-metabolizing activity, and cytochrome P-450 increased, but glucose-6-phosphatase activity was not changed. The induction of drug-metabolizing enzymes and absence of toxicity were evidence that the hepatomegaly was an adaptation to an increased functional load in the liver. An increase in catalase activity suggested that the response may have also involved peroxisomes. In addition to rats, LY171883 administration caused hepatomegaly in mice and hamsters at daily exposures exceeding 100 mg/kg. The response was not observed in guinea pigs, beagle dogs, or rhesus monkeys given maximum tolerated doses, indicating LY171883-induced hepatomegaly is not a response common to all species. The doses required to elicit hepatomegaly greatly exceeded doses that produce pharmacological efficacy in animals and those that are expected to be used clinically. Since humans will not receive doses comparable to those given rodents, and considering that the primate species tested did not experience hepatomegaly, it is unlikely that the effect observed in rodents can be extrapolated to humans.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0272-0590
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
794-803
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:3840108-Acetophenones,
pubmed-meshheading:3840108-Animals,
pubmed-meshheading:3840108-Azoles,
pubmed-meshheading:3840108-Cricetinae,
pubmed-meshheading:3840108-DNA,
pubmed-meshheading:3840108-Dose-Response Relationship, Drug,
pubmed-meshheading:3840108-Hepatomegaly,
pubmed-meshheading:3840108-Liver,
pubmed-meshheading:3840108-Male,
pubmed-meshheading:3840108-Mesocricetus,
pubmed-meshheading:3840108-Mice,
pubmed-meshheading:3840108-Mice, Inbred Strains,
pubmed-meshheading:3840108-Mitochondria, Liver,
pubmed-meshheading:3840108-Organ Size,
pubmed-meshheading:3840108-Oxygen Consumption,
pubmed-meshheading:3840108-Rats,
pubmed-meshheading:3840108-Rats, Inbred F344,
pubmed-meshheading:3840108-Species Specificity,
pubmed-meshheading:3840108-Tetrazoles
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
Characterization of liver enlargement induced by compound LY171883 in rats.
|
| pubmed:publicationType |
Journal Article
|